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There is no literature regarding the contraception practices in female CF patients. A chart review identified 69 women with CF of whom two
thirds were using contraception. Eleven different forms of contraception were being used with the oral contraceptive pill the preferred method.
Despite theoretical concerns regarding efficacy and toxicity, the choices of contraception are similar to those of the general U.S. population.
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Contraceptive choices and reproductive health are important
issues for patients with CF as median life expectancy increases
[1,2]. Concerns have been raised regarding oral contraceptive
pill (OCP) usage in CF due to potential malabsorption, and CF
liver disease could result in either high serum levels as a con-
sequence of decreased hydroxylated estrogens or decreased
serum levels secondary to decreased glucurconide-conjugated
estrogens impairing enterohepatic circulation of estrogens [3,4].
There is no difference in sexual practice between CF and age
matched females [5] but pregnancy in CF women is associated
with increased health care requirements [6,7] The expert
opinion of the U.S. CF Foundation Consensus Statement re-
garding adult care suggests that “issues of female contraception
are broadly similar for women with and without CF” [2].
Evidence in support of this assertion, however, is lacking. In☆ Supported by a clinical fellowship grant from the Cystic Fibrosis
Foundation and a traveling studentship in medicine from the National University
of Ireland.
⁎ Corresponding author. Division of Pulmonary and CCM, UWMC, 1959 NE
Pacific St, Box 356522, Seattle WA 98195-6522, United States.
E-mail address: moira@u.washington.edu (M.L. Aitken).
1569-1993/$ - see front matter © 2008 European Cystic Fibrosis Society. Publishe
doi:10.1016/j.jcf.2008.03.001order to address the issue of contraception practices and choices
in women with CF we examined contraception choices in all
female CF patients attending the University of Washington's
Adult CF clinic.
2. Methods
A retrospective chart review was performed on all female CF
patients attending the University of Washington Adult CF clinic
in 2004. Factors measured to determine clinical phenotype were
age, the first FEV1% predictedmeasured in that calendar year, the
first body mass index (BMI) measured in that calendar year,
presence of pancreatic insufficiency (defined as ongoing oral
pancreatic enzyme therapy), presence of liver disease (defined as
twice normal elevated liver function tests or known portal
hypertension) and CF genotype [8,9]. All contraception choices
were recorded. If a woman used two different contraceptive
choices in the year, thiswas recorded. This studywas approved by
the Institutional Review Board of the University of Washington.
Description was used for analysis.
3. Results
The characteristics of the CF women attending the clinic in
2004 (n = 69) are summarized in Table 1. Contraception choices
among CF women patients are highlighted in Table 2. The rated by Elsevier B.V. All rights reserved.
Table 1
Characteristics of CF women
2004
n=69
Age in years Median 28
(Range) 15–56
BMI in kg/m2 Median 20.1
(Range) 14.8–37.6
FEV1 % Pred. Median 53
(Range) 16–112
Pancreatic insufficient 62 (90%)
PI+OCP 17/18
Liver disease 5 (7%)
Liver disease+OCP 0/69
Class CFTR mutation (%)
1 2%
2 71%
3 6%
4 4%
5 3%
Unknown 14%
OCP=oral contraceptive pill. PI=pancreatic insufficiency.
Table 2
Contraceptive choices in CF women
Contraceptive method 2004
Total n=69 (%)
OCP 18 (26%)
Abstinence/ NFP 12 (17%)
Condom 8 (12%)
Tubal ligation 7 (10%)
Transdermal patch 4 (6%)
Vasectomy 3 (4%)
Depot 3 (4%)
Post-menopausal 3 (4%)
Pregnant 3 (4%)
Vaginal ring 1 (1%)
Hysterectomy 1 (1%)
Unknown 6 (9%)
OCP=oral contraceptive pill. NFP=natural family planning. Vasectomy=va-
sectomy in partner. Depot=depot medroxyprogesterone acetate.
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excluding abstinence as a means of contraception. The oral
contraceptive pill (OCP) was the preferred choice of contra-
ception with 26% of the patients using this method (Table 2).
Lack of documentation of contraception choices represented
9%. One patient was on no contraception at the beginning of
the year but later transitioned to depot medroxyprogesterone
acetate, and another patient using the Eastradiol patch changed
to an Intra Uterine Device (IUD). Ninety four percent (n=17/18)
of the OCP group was pancreatic insufficient. The OCP brands
used were low dose estrogen. None of the patients with known
liver disease (n=5) were using the OCP.
Overall contraceptive use of CF women was high (70%
excluding abstinence, pregnancy and unknown) and similar to
that of non-CF women in the U.S. (62%) [10]. Overall OCP was
the commonest form (26%) of contraception in CF women,
again similar to national estimates of 19% of women aged 15–
44 years [10]. More CF patient women practiced natural family
planning or abstinence 17% in comparison with national data
of 1% [10].
4. Discussion
This is the first study to document female contraception
choices in CF women. Our study shows that the large majority
of CF women in the U.S. Pacific Northwest are making active
contraception choices with eleven different forms of contra-
ception being used of which the OCP is the most common.
Newer contraceptive devices include contraceptive patches
[Ortho Evra Patch (n=4)] and contraceptive vaginal rings
[Nuvaring (n=1)] [11]. The attraction of a weekly topical patch
or monthly vaginal ring contraception is their relative prolonged
duration of action [11]. In 2005, the FDA updated labeling for
the Ortho Evra contraceptive patch warning healthcareproviders and patients that the patch exposes women to higher
levels of estrogen than most OCPs [12]. Indeed the only con-
traceptive failure in 2004 was a patient using the Ortho Evra
contraceptive patch over the summer months. We hypothesize
that this could occur because of increased sweat production or
the elevated sweat sodium or chloride. However, the patch did
appear to remain efficacious in non-CF women under condi-
tions of heat, humidity, and exercise [13].
In the general population, lack of compliance is the primary
reason for OCP failure. In a large study of over 600 non-CF
women taking the OCP full compliance improves with age from
68% in the 18 to 19 year olds to 85% in the 30 to 34 year olds
[14]. Given that our OCP group is young, highlights the im-
portance of emphasizing full compliance in patients attending
CF clinic. The fact that 94% of women using the OCP were
pancreatic insufficient and yet no known contraceptive failures
occurred suggests that concerns regarding poor absorption of
hormones from the gastrointestinal tract may be overstated [3].
Concerns have also been raised regarding interaction of the
OCP with antibiotics. A recent review of the pharmacokinetic
data regarding the efficacy of oral contraceptives when used
concomitantly with antibiotic therapy demonstrates that plasma
levels of oral contraceptive steroids are unchanged with the
concomitant administration of many antibiotics used widely in
CF, including ampicillin, ciprofloxacin, clarithromycin, dox-
ycycline, metronidazole, ofloxacin, roxithromycin, temaflox-
acin, and tetracycline. Treatment with rifampin can alter plasma
hormone levels [14] however, this agent is rarely used in CF
care.
As a single center study from the Pacific Northwest of the U.S.,
our findings may not be representative of the national or inter-
national population of women with CF. We also failed to capture
the contraceptive choices in 9% of CF women, which might have
produced slightly different results.
We recommend that accurate documentation of contra-
ceptive choices is very important in CF clinics as one element of
reproductive counseling.
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